B-intervention	0	12	Levofloxacin
O	13	16	for
O	17	28	prophylaxis
O	29	31	in
O	32	38	breast
O	39	45	cancer
O	46	53	surgery
O	54	62	compared
O	63	67	with
B-control	68	77	ofloxacin
O	77	78	.

O	79	81	We
O	82	87	found
O	88	92	that
O	93	97	once
O	97	98	-
O	98	103	daily
O	104	107	use
O	108	110	of
O	111	120	ofloxacin
O	121	123	is
O	124	134	beneficial
O	135	139	from
O	140	143	the
O	144	155	standpoints
O	156	158	of
O	159	166	economy
O	167	170	and
O	171	178	patient
O	179	189	compliance
O	189	190	.

O	191	203	Levofloxacin
O	203	204	,
O	205	208	has
O	209	214	twice
O	215	218	the
O	219	232	antimicrobial
O	233	241	activity
O	242	245	and
O	246	250	same
O	251	259	toxicity
O	260	262	of
O	263	272	ofloxacin
O	272	273	.

O	274	276	We
O	277	289	investigated
O	290	293	the
O	294	302	clinical
O	303	313	usefulness
O	314	316	of
O	317	329	levofloxacin
O	330	338	compared
O	339	343	with
O	344	353	ofloxacin
O	354	356	in
O	357	363	breast
O	364	371	surgery
O	371	372	.

O	373	380	Between
O	381	385	July
O	385	386	,
O	387	391	1996
O	392	395	and
O	396	401	April
O	401	402	,
O	403	407	1999
O	407	408	,
B-total-participants	409	412	199
O	413	424	consecutive
B-eligibility	425	433	patients
I-eligibility	434	446	hospitalized
I-eligibility	447	449	in
I-eligibility	450	453	our
I-eligibility	454	464	department
I-eligibility	465	468	for
I-eligibility	469	478	treatment
I-eligibility	479	481	of
I-eligibility	482	488	breast
I-eligibility	489	495	cancer
O	496	500	were
O	501	509	enrolled
O	510	512	in
O	513	517	this
O	518	523	study
O	524	528	with
O	529	534	their
O	535	543	informed
O	544	551	consent
O	552	555	and
B-total-participants	556	559	181
O	560	568	patients
O	569	573	were
O	574	583	evaluated
O	583	584	.

B-iv-bin-abs	585	589	Four
O	590	591	(
B-iv-bin-percent	591	592	4
I-iv-bin-percent	592	593	%
O	593	594	)
O	595	597	of
O	598	601	the
B-intervention-participants	602	604	99
O	605	613	patients
O	614	616	in
O	617	620	the
O	621	633	levofloxacin
O	634	639	group
O	640	643	had
B-outcome	644	649	wound
I-outcome	650	660	infections
O	660	661	,
O	662	664	as
O	665	668	did
B-cv-bin-abs	669	670	5
O	671	672	(
B-cv-bin-percent	672	673	6
I-cv-bin-percent	673	674	%
O	674	675	)
O	676	678	of
O	679	682	the
B-control-participants	683	685	82
O	686	694	patients
O	695	697	in
O	698	701	the
O	702	711	ofloxacin
O	712	717	group
O	717	718	.

O	719	722	The
B-outcome	723	729	median
I-outcome	730	735	times
I-outcome	736	742	needed
I-outcome	743	746	for
I-outcome	747	752	wound
I-outcome	753	757	care
O	757	758	,
O	759	763	with
O	764	768	25th
O	769	772	and
O	773	777	75th
O	778	789	percentiles
O	789	790	,
O	791	795	were
B-iv-cont-median	796	798	13
O	799	800	[
B-iv-cont-q1	800	801	9
O	801	802	,
B-iv-cont-q3	803	805	16
O	805	806	]
O	807	811	days
O	812	814	in
O	815	818	the
O	819	831	levofloxacin
O	832	837	group
O	838	841	and
B-cv-cont-median	842	844	11
O	845	846	[
B-cv-cont-q1	846	847	9
O	847	848	,
B-cv-cont-q3	849	851	16
O	851	852	]
O	853	857	days
O	858	860	in
O	861	864	the
O	865	874	ofloxacin
O	875	880	group
O	880	881	.

O	882	886	From
O	887	895	infected
O	896	901	wound
B-iv-bin-abs	902	907	three
O	908	915	strains
O	916	918	of
B-outcome	919	933	Staphylococcus
I-outcome	934	940	aureus
O	941	945	were
O	946	954	detected
O	955	959	from
O	960	963	the
O	964	976	levofloxacin
O	977	982	group
O	983	986	and
B-cv-bin-abs	987	990	two
O	991	998	strains
O	999	1003	were
O	1004	1008	from
O	1009	1018	ofloxacin
O	1019	1024	group
O	1024	1025	,
O	1026	1029	but
O	1030	1032	no
O	1033	1044	methicillin
O	1044	1045	-
O	1045	1054	resistant
O	1055	1062	strains
O	1063	1067	were
O	1068	1076	isolated
O	1076	1077	.

O	1078	1086	Multiple
O	1087	1097	regression
O	1098	1106	analysis
O	1107	1113	showed
O	1114	1118	that
O	1119	1123	only
O	1124	1129	wound
O	1130	1140	dehiscence
O	1141	1144	was
O	1145	1146	a
O	1147	1158	significant
O	1159	1165	factor
O	1166	1168	in
O	1169	1172	the
O	1173	1183	occurrence
O	1184	1186	of
O	1187	1192	wound
O	1193	1202	infection
O	1203	1206	and
O	1207	1210	the
O	1211	1217	period
O	1218	1220	of
O	1221	1226	wound
O	1227	1231	care
O	1231	1232	.

O	1233	1235	No
O	1236	1241	signs
O	1242	1244	or
O	1245	1253	symptoms
O	1254	1264	suggesting
O	1265	1277	levofloxacin
O	1278	1280	or
O	1281	1290	ofloxacin
B-outcome	1291	1299	toxicity
O	1300	1304	were
O	1305	1313	observed
O	1313	1314	.

O	1315	1325	Laboratory
O	1326	1330	test
O	1331	1338	changes
O	1339	1345	before
O	1346	1349	and
O	1350	1355	after
O	1356	1365	treatment
O	1366	1370	were
O	1371	1378	similar
O	1379	1381	in
O	1382	1385	the
O	1386	1389	two
O	1390	1396	groups
O	1396	1397	.

O	1398	1400	It
O	1401	1408	appears
O	1409	1413	that
O	1414	1426	levofloxacin
O	1427	1429	is
O	1430	1433	not
O	1434	1442	superior
O	1443	1445	to
O	1446	1455	ofloxacin
O	1456	1458	in
O	1459	1471	prophylactic
O	1472	1480	efficacy
O	1481	1484	for
O	1485	1498	postoperative
O	1499	1504	wound
O	1505	1514	infection
O	1515	1520	after
O	1521	1527	breast
O	1528	1535	surgery
O	1535	1536	.
